The SNAP trial includes all age groups because people of all ages, from newborn babies to the elderly, suffer from Staph aureus bloodstream infections, and the treatments are usually the same. This trial will work out how best to treat people of all ages with Staph aureus bloodstream infections.
A summary of how Staphylococcus aureus and penicillin have been instrumental in both the success and failure of one another since they met. Carly Botheras (PhD Candidate, Geelong Centre for Emerging Infectious Diseases, Barwon Health)
Amy Legg (Clinical Pharmacist) and Prof Marc Scheetz (Professor of Pharmacy and Pharmacology at Midwestern University) explain one of the proposed SNAP substudies involving novel urinary biomarkers.
Prof Steven Tong presented the SNAP Trial as part of the Australian Clinical Trials Alliance's (ACTA) series of resources related to simplified consent in comparative effectiveness trials.
Amy Legg (Clinical Pharmacist) and Prof Marc Scheetz (Professor of Pharmacy and Pharmacology at Midwestern University) provide an overview of the renal toxicity of vancomycin.
The SNAP Trial includes consumer representation on the global trial steering committee. Read our consumer representative's experience of being hospitalised with S. Aureus bacteraemia.
Josh Davis, co-lead of the SNAP trial, writes about how the trial got to where it is today.
